US in talks on Europe missile co-production, source says

The U.S. is in talks with Germany and other European nations to enable co-production and a Europe-based maintenance facility for Lockheed’s PAC-3 Patriot and Raytheon’s AIM-120 AMRAAM missiles, with a statement of intent planned at a NATO Industry Forum during Ankara’s summit. If implemented, the plan is intended to relieve capacity constraints at U.S. factories and support higher production levels at home to meet elevated demand driven by the Ukraine war. The article frames this as aligned with recent U.S. Defense Production Act efforts to address munitions supply and manufacturing bottlenecks.

Analysis

This is less a demand story than a throughput story: the value is in converting an already-crowded backlog faster and with less working-capital drag. RTX is the cleaner beneficiary because AMRAAM is the higher-velocity production item, so any European co-production should translate into faster unit turns and better line utilization over the next 2-4 quarters. LMT benefits too, but the PAC-3 angle looks more like a service/maintenance annuity than a pure volume kicker, which is good for cash flow stability but less explosive for margins.

Second-order effects matter here. If Europe takes on more assembly and maintenance work, U.S. primes gain de-bottlenecking relief, while selected European industrials and electronics subcontractors get a multi-year qualification pipeline. The flip side is that some of the scarcity premium embedded in missile names could compress if investors conclude capacity constraints are easing faster than feared; that would matter more for multiple expansion than for near-term earnings. Over 6-18 months, localization also shifts more content outside the U.S., which may cap gross margins but reduces political/regulatory risk and lowers delivery slippage.

The key risk is that this is still a statement-of-intent, not funded volume. If appropriations, workshare negotiations, or NATO procurement timing slip, the market can fade the headline within days. The contrarian view is that consensus may be overfocusing on "more demand" when the bigger implication is "less bottleneck"; that is constructive for execution, but not necessarily for multiple expansion unless management raises missile output guidance at the next print.

Key Decisions for Investors

• Prefer RTX over LMT on weakness for a 3-6 month trade; AMRAAM co-production is the cleaner near-term throughput catalyst and should show up faster in missile delivery guidance.
• Add to LMT only if management later confirms PAC-3 maintenance capacity adds recurring revenue without margin dilution; otherwise treat as a lower-beta hold rather than an aggressive buy.
• Use any post-headline spike in both names to fade into earnings unless there is a signed, funded contract or explicit FY25/FY26 production uplift; the thesis is contract execution, not sentiment.
• Watch for contract awards and appropriations over the next 30-90 days; if they do not materialize, reduce exposure because the move is likely to retrace once the headline premium fades.